{
  "content": "JACC Heart Fail. 2013; 1:21-28\nCrossref\nScopus (141)\nPubMed\nGoogle Scholar\nBeta-blockers may, however, be preferable in HFrEF over other options, due to the negative inotropic effects of drugs such as verapamil, and potential adverse effects of digoxin.59–61\n59.\nWasham, J.B. ∙ Stevens, S.R. ∙ Lokhnygina, Y. ∙ et al.\nDigoxin use in patients with atrial fibrillation and adverse cardiovascular outcomes: a retrospective analysis of the rivaroxaban once daily oral direct factor xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation (ROCKET AF)\nLancet. 2015; 385:2363-2370\nFull Text\nFull Text (PDF)\nScopus (120)\nPubMed\nGoogle Scholar\n60.\nOsman, M.H. ∙ Farrag, E. ∙ Selim, M. ∙ et al.",
  "source": "https://www.thelancet.com/journals/lanepe/article/PIIS2666-7762(23)00220-X/fulltext",
  "chunk_id": "7cf929d1-f9bc-46ff-a3a9-822ce9c2fcd3",
  "similarity_score": 0.18140780925750732,
  "query": "beta-blockers safety profile atrial fibrillation heart failure contraindications bradycardia hypotension",
  "rank": 49,
  "title": "Atrial fibrillation: better symptom control with rate and rhythm management",
  "authors": "Dhiraj Gupta, Michiel Rienstra, Isabelle C. van Gelder, Laurent Fauchier",
  "year": "2024",
  "journal": "The Lancet Regional Health – Europe",
  "reference": "Gupta, D., Rienstra, M., van Gelder, I. C., & Fauchier, L. (2024). Atrial fibrillation: better symptom control with rate and rhythm management. The Lancet Regional Health – Europe, 37100801. https://doi.org/10.1016/j.lanepe.2023.100801",
  "doi": "10.1016/j.lanepe.2023.100801",
  "chunk_index": 91,
  "total_chunks": 154,
  "retrieved_at": "2025-07-24T21:57:55.188810"
}